Kidder Stephen W Sells 500 Shares of Bristol-Myers Squibb Company (BMY)

Kidder Stephen W cut its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 8.8% during the first quarter, Holdings Channel reports. The firm owned 5,200 shares of the biopharmaceutical company’s stock after selling 500 shares during the period. Kidder Stephen W’s holdings in Bristol-Myers Squibb were worth $283,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Union Bankshares Corp boosted its stake in Bristol-Myers Squibb by 12.2% in the first quarter. Union Bankshares Corp now owns 4,405 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 480 shares during the last quarter. Doyle Wealth Management purchased a new stake in Bristol-Myers Squibb during the first quarter worth approximately $14,571,000. Philadelphia Trust Co. boosted its stake in Bristol-Myers Squibb by 7.7% in the fourth quarter. Philadelphia Trust Co. now owns 20,924 shares of the biopharmaceutical company’s stock worth $1,223,000 after buying an additional 1,500 shares during the last quarter. National Pension Service boosted its stake in Bristol-Myers Squibb by 3.7% in the first quarter. National Pension Service now owns 1,120,621 shares of the biopharmaceutical company’s stock worth $62,038,000 after buying an additional 39,713 shares during the last quarter. Finally, Meridian Management Co. boosted its stake in Bristol-Myers Squibb by 1.5% in the first quarter. Meridian Management Co. now owns 51,770 shares of the biopharmaceutical company’s stock worth $2,815,000 after buying an additional 770 shares during the last quarter. Institutional investors own 69.79% of the company’s stock.

Bristol-Myers Squibb Company (NYSE:BMY) traded up 0.25% on Friday, hitting $56.73. 4,060,530 shares of the company were exchanged. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $60.86. The stock’s 50-day moving average price is $55.80 and its 200-day moving average price is $54.64. The stock has a market capitalization of $93.03 billion, a P/E ratio of 20.72 and a beta of 1.17.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.69 EPS. On average, equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.97 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 2.75%. The ex-dividend date was Wednesday, July 5th. Bristol-Myers Squibb’s payout ratio is 56.73%.

COPYRIGHT VIOLATION WARNING: “Kidder Stephen W Sells 500 Shares of Bristol-Myers Squibb Company (BMY)” was first posted by Week Herald and is the property of of Week Herald. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://weekherald.com/2017/08/12/kidder-stephen-w-sells-500-shares-of-bristol-myers-squibb-company-bmy.html.

A number of equities research analysts have commented on BMY shares. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 target price on the stock in a research note on Monday, June 5th. Jefferies Group LLC restated a “buy” rating and set a $64.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, June 5th. BidaskClub upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Robert W. Baird started coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 25th. They set an “outperform” rating on the stock. Finally, Deutsche Bank AG set a $55.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $62.12.

In other news, Director Theodore R. Samuels II acquired 6,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, August 2nd. The stock was purchased at an average cost of $55.94 per share, with a total value of $335,640.00. Following the purchase, the director now owns 18,000 shares in the company, valued at $1,006,920. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.23% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply